Mitochondria determine the efficacy of anticancer agents that interact with DNA but not the cytoskeleton

Journal of Pharmacology and Experimental Therapeutics

Volumn 337, Issue 3, 2011, Pages 838-845

  Hara, Kenjirou ^a,b   Kasahara, Emiko ^a,c   Takahashi, Nozomi ^a   Konishi, Masami ^a   Inoue, June ^a   Jikumaru, Mika ^a   Kubo, Shuji ^c   Okamura, Haruki ^c   Sato, Eisuke ^a   Inoue, Masayasu ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Iwata Chemical Co Ltd   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BUSULFAN; CASPASE 3; CASPASE 9; CISPLATIN; COLCHICINE; CYTOCHROME C; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; MITOCHONDRIAL DNA; PACLITAXEL; REACTIVE OXYGEN METABOLITE; VINBLASTINE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOSKELETON; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME RELEASE; HUMAN; HUMAN CELL; MESOTHELIOMA; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL DEATH; CELL LINE, TUMOR; CYTOCHROMES C; CYTOSKELETON; DNA; DNA, MITOCHONDRIAL; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MESOTHELIOMA; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; REACTIVE OXYGEN SPECIES;

EID: 79956209042     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.179473     Document Type: Article

References (43)

1. Akiyama Y, Ma Q, Edgar E, Laikhter A, and Hecht SM (2008) Identification of strong DNA binding motifs for bleomycin. J Am Chem Soc 130:9650-9651.
2. Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, et al. (1981) Sequence and organization of the human mitochondrial genome. Nature 290:457-465. (Pubitemid 11159074)
3. Baldini N (1997) Multidrug resistance-a multiplex phenomenon. Nat Med 3:378-380.
4. Bhalla KN (2003) Microtubule-targeted anticancer agents and apoptosis. Oncogene 22:9075-9086.
5. 2 and bleomycin-induced oxidative stress in L6C5 rat myoblasts. Free Radic Biol Med 35:1355-1364.
6. Chang B, Nishikawa M, Sato E, Utsumi K, and Inoue M (2002) L-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine. Arch Biochem Biophys 405:55-64. (Pubitemid 35026166)
7. Chen JG and Horwitz SB (2002) Differential mitotic responses to microtubulestabilizing and -destabilizing drugs. Cancer Res 62:1935-1938.
8. Faulkner KM, Liochev SI, and Fridovich I (1994) Stable Mn(III) porphyrins mimic superoxide dismutase in vitro and substitute for it in vivo. J Biol Chem 269:23471-23476. (Pubitemid 24293545)
9. Fuertes MA, Alonso C, and Pérez JM (2003) Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev 103:645-662.
10. Fulda S, Galluzzi L, and Kroemer G (2010) Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 9:447-464.
11. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727-741.
12. Gilleron M, Marechal X, Montaigne D, Franczak J, Neviere R, and Lancel S (2009) NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis. Biochem Biophys Res Commun 388:727-731.
13. Green DR and Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 305:626-629. (Pubitemid 39006738)
14. Halestrap AP, Woodfield KY, and Connern CP (1997) Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase. J Biol Chem 272:3346-3354. (Pubitemid 27066829)
15. Han D, Williams E, and Cadenas E (2001) Mitochondrial respiratory chain-dependent generation of superoxide anion and its release into the intermembrane space. Biochem J 353:411-416. (Pubitemid 32096952)
16. Hudis CA (2007) Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357:39-51.
17. Kane DJ, Sarafian TA, Anton R, Hahn H, Gralla EB, Valentine JS, Ord T, and Bredesen DE (1993) Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 262:1274-1277. (Pubitemid 24036095)
18. Kim HJ, Lee JH, Kim SJ, Oh GS, Moon HD, Kwon KB, Park C, Park BH, Lee HK, Chung SY, et al. (2010) Roles of NADPH oxidases in cisplatin-induced reactive oxygen species generation and ototoxicity. J Neurosci 30:3933-3946.
19. King MP and Attardi G (1989) Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 246:500-503. (Pubitemid 19273941)
20. Kutuk O and Letai A (2008) Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res 68:7985-7994.
21. Lenaz G (1998) Role of mitochondria in oxidative stress and ageing. Biochim Biophys Acta 1366:53-67.
22. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, and Wang X (1997) Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479-489. (Pubitemid 27508237)
23. Luo X, Budihardjo I, Zou H, Slaughter C, and Wang X (1998) Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94:481-490. (Pubitemid 28391864)
24. Mendelsohn J and Baselga J (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19:6550-6565. (Pubitemid 32197693)
25. Mielgo A, Torres VA, Clair K, Barbero S, and Stupack DG (2009) Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules. Oncogene 28:3551-3562.
26. Momparler RL, Karon M, Siegel SE, and Avila F (1976) Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res 36:2891-2895.
27. Ogretmen B, Bahadori HR, McCauley MD, Boylan A, Green MR, and Safa AR (1998) Co-ordinated over-expression of the MRP and γ-glutamylcysteine synthetase genes, but not MDR1, correlates with doxorubicin resistance in human malignant mesothelioma cell lines. Int J Cancer 75:757-761. (Pubitemid 28145824)
28. Pacheco DY, Stratton NK, and Gibson NW (1989) Comparison of the mechanism of action of busulfan with hepsulfam, a new antileukemic agent, in the L1210 cell line. Cancer Res 49:5108-5110. (Pubitemid 19239353)
29. Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, et al. (2002) Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 1587:194-205. (Pubitemid 34655788)
30. Petrosillo G, Ruggiero FM, and Paradies G (2003) Role of reactive oxygen species and cardiolipin in the release of cytochrome c from mitochondria. FASEB J 17:2202-2208. (Pubitemid 37509576)
31. Qian W, Nishikawa M, Haque AM, Hirose M, Mashimo M, Sato E, and Inoue M (2005) Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death. Am J Physiol Cell Physiol 289:C1466-C1475. (Pubitemid 41636351)
32. Ramachandran A, Moellering DR, Ceaser E, Shiva S, Xu J, and Darley-Usmar V (2002) Inhibition of mitochondrial protein synthesis results in increased endothelial cell susceptibility to nitric oxide-induced apoptosis. Proc Natl Acad Sci USA 99:6643-6648. (Pubitemid 34526186)
33. Ravid A, Rocker D, Machlenkin A, Rotem C, Hochman A, Kessler-Icekson G, Liberman UA, and Koren R (1999) 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res 59:862-867. (Pubitemid 29086740)
34. Rostovtseva TK and Bezrukov SM (2008) VDAC regulation: role of cytosolic proteins and mitochondrial lipids. J Bioenerg Biomembr 40:163-170.
35. Saitou N (1991) Reconstruction of molecular phylogeny of extant hominoids from DNA sequence data. Am J Phys Anthropol 84:75-85.
36. Soini Y, Järvinen K, Kaarteenaho-Wiik R, and Kinnula V (2001) The expression of P-glycoprotein and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) in human malignant mesothelioma. Ann Oncol 12:1239-1245. (Pubitemid 32994751)
37. Tomek S, Emri S, Krejcy K, and Manegold C (2003) Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Br J Cancer 88:167-174. (Pubitemid 36258399)
38. von Haefen C, Wieder T, Essmann F, Schulze-Osthoff K, Dörken B, and Daniel PT (2003) Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop. Oncogene 22:2236-2247. (Pubitemid 36566780)
39. Wang Y, He QY, Sun RW, Che CM, and Chiu JF (2005) GoldIII porphyrin 1a induced apoptosis by mitochondrial death pathways related to reactive oxygen species. Cancer Res 65:11553-11564. (Pubitemid 41821714)
40. Waterhouse NJ, Goldstein JC, von Ahsen O, Schuler M, Newmeyer DD, and Green DR (2001) Cytochrome c maintains mitochondrial transmembrane potential and ATP generation after outer mitochondrial membrane permeabilization during the apoptotic process. J Cell Biol 153:319-328. (Pubitemid 34280218)
41. Wieder T, Essmann F, Prokop A, Schmelz K, Schulze-Osthoff K, Beyaert R, Dörken B, and Daniel PT (2001) Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood 97:1378-1387. (Pubitemid 32183762)
42. Yakes FM and Van Houten B (1997) Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci USA 94:514-519. (Pubitemid 27053665)
43. Yin XM, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, Roth KA, and Korsmeyer SJ (1999) Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 400:886-891. (Pubitemid 29406726)